MARKET

SKYE

SKYE

Skye Bioscience
NASDAQ
1.700
-0.100
-5.56%
After Hours: 1.700 0 0.00% 19:30 09/24 EDT
OPEN
1.800
PREV CLOSE
1.800
HIGH
1.867
LOW
1.700
VOLUME
37.39K
TURNOVER
--
52 WEEK HIGH
39.92
52 WEEK LOW
1.500
MARKET CAP
7.53M
P/E (TTM)
-0.1670
1D
5D
1M
3M
1Y
5Y
1D
Major Insider Moves Shake Up Skye Bioscience
TipRanks · 1h ago
Weekly Report: what happened at SKYE last week (0914-0918)?
Weekly Report · 3d ago
Major Insider Moves Shake Up Skye Bioscience
TipRanks · 6d ago
Weekly Report: what happened at SKYE last week (0907-0911)?
Weekly Report · 09/14 09:14
Skye Bioscience CFO Resigns, CEO Assumes Financial Role
TipRanks · 09/11 20:29
Skye Bioscience Announces Resignation Of CFO John Sharp Effective September 8; Appoints CEO Punit Dhillon As Principal Financial And Accounting Officer
Benzinga · 09/11 20:16
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 09/09 17:06
Weekly Report: what happened at SKYE last week (0831-0904)?
Weekly Report · 09/07 09:13
More
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

Webull offers Skye Bioscience Inc stock information, including NASDAQ: SKYE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SKYE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SKYE stock methods without spending real money on the virtual paper trading platform.